This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 2 of 590

Ocular Therapeutix Eye-Pain Plug Flops Confirmatory Pivotal Trial

By Adam Feuerstein

Plans to seek U.S. approval for the Ocular device, known as OTX-DP are now up in the air.

05:22PM 04/06/15

Biotech Stock Mailbag: Northwest Bio, Intrexon, Ziopharm

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

05:57AM 04/02/15

The Top-Performing Biotech Stock During a Sizzling First Quarter

By Adam Feuerstein

That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.

09:30AM 04/01/15

Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame

By Adam Feuerstein

Current Sarepta Chief Medical Officer Ed Kaye is taking over the CEO role on an interim basis until a permanent chief can be found to replace Chris Garabedian.

09:57PM 03/31/15

Bankrupt Introgen Seeks Reincarnation IPO in Biotech Bubble

By Adam Feuerstein

Will the biotech bubble support the comeback of Introgen Therapeutics, one of the sector's largest disasters?

11:30AM 03/31/15

Genfit's French Fans Fume Following Failure of Fatty Liver Drug

By Adam Feuerstein

French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.

08:51AM 03/31/15

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

By Adam Feuerstein

Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.

10:43AM 03/30/15

Teva Buying Auspex Pharma for $3.5 Billion in Bid to Restart Growth

By Adam Feuerstein

Teva said it would acquire smaller companies as a way to offset the expected revenue hit coming when its multiple sclerosis drug Copaxone faces generic competition in September.

07:41AM 03/30/15

Horizon Pharma Buying Orphan Drugmaker Hyperion for $1.1 Billion

By Adam Feuerstein

Horizon is buying Hyperion to grow its orphan disease business unit.

06:38AM 03/30/15

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study

By Adam Feuerstein

The GFT505 study in NASH failed, analysts said. That's bad for Genfit and good for Intercept Pharmaceuticals, which is developing a rival drug for fatty liver known as OCA.

09:40AM 03/27/15

Page 2 of 590

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs